Based near Copenhagen, the acquired company specializes in producing active pharmaceutical ingredients and advanced intermediates, with a particular focus on controlled substances used in treatments for opioid use disorder and ADHD. Its cGMP-certified facility has maintained commercial production since 2015, serving pharmaceutical markets across Europe, North America, and the Middle East. Financial details of the transaction remain undisclosed.
In section Releases
Samfara Acquires API Manufacturer Chr. Olesen Synthesis
London-based life sciences investor Samfara has acquired Danish manufacturer Chr. Olesen Synthesis, marking the firm's debut investment. The deal, involving a syndicate of institutional investors and family offices, shifts ownership from Chr. Olesen and Signet Healthcare Partners to the private equity firm while keeping current leadership in place.
Following the acquisition, Jean-François Hilaire, formerly of Unither and Recipharm, will join the board as Chair. Samfara partners Helena Malchione and James Cocker stated the investment aligns with their strategy of targeting companies in complex niches that require both capital and operational support. CEO Thomas Moestrup, who is investing alongside the new owners, intends to use the partnership to pursue both organic growth and potential future acquisitions.
Comments (0)
No comments yet. Be the first!